|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
ApoE4 which differs from apoE3 by the single amino acid substitution Cys112Arg is also associated with dyslipidemia although binding of this isoform to the LDLR is unaffected.
|
25328986 |
2014 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Prevalence of the apolipoprotein E Arg145Cys dyslipidemia at-risk polymorphism in African-derived populations.
|
24239320 |
2014 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
APOE genotypes are associated with lipid levels in patients with RA, and may contribute to dyslipidemia in some patients.
|
23613766 |
2013 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The purpose of the study was to examine the distribution of APOE gene polymorphism and the influence of which as well as occupational environment on dyslipidemia and overweight in Chinese civil aircrews.
|
23159296 |
2013 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Activation of renin-angiotensin system is involved in dyslipidemia-mediated renal injuries in apolipoprotein E knockout mice and HK-2 cells.
|
23570453 |
2013 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E gene polymorphisms are strong predictors of inflammation and dyslipidemia in rheumatoid arthritis.
|
22174202 |
2012 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This study sought to determine the association of apoE gene polymorphism with hyperuricemia and dyslipidemia in young healthy people.
|
22540367 |
2012 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
None of the combined APOA5-APOE polymorphisms increased risk for dyslipidemia.
|
21132386 |
2011 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Multivariate logistic regression analysis was used to assess whether APOE genotype, BMI, and dyslipidemia are associated with mortality, adjusting for potential confounders.
|
21595502 |
2011 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, the LDL-receptor binding defects for these apoE variants do not correlate well with the severity of dyslipidemia, indicating that these variants may carry additional properties that contribute to their pathogenic potential.
|
22069485 |
2011 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We assessed individual apoE genotypes and lipid blood profile in a total of 463 patients followed at a specialized lipid clinic due to dyslipidemia, with a 3-year median follow-up time.
|
21450082 |
2011 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The prevention of apoE4[R142C]-induced dyslipidemia by deletion of the 203-299 residues suggests that, in the full-length protein, the R142C substitution may have altered the conformation of apoE bound to VLDL/IDL/LDL in ways that prevent triglyceride hydrolysis, cholesterol esterification, and receptor-mediated clearance in vivo.
|
20861163 |
2011 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This study investigated whether apoE variants influence the prevalence of cardiovascular risk factors (obesity, diabetes and dyslipidaemia), in patients receiving antipsychotic treatment, due to extension of the risk seen in the general population, but also due to the role of the APOE gene in mediating antipsychotic-induced side effects.
|
19541455 |
2009 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoprotein.
|
17655277 |
2007 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Compared with APOE*3/*3 homozygotes, patients with the APOE*4 allele had 1.3 times higher risk for CAD after ignoring dyslipidemia, but this risk was modified after adjusting for dyslipidemia.
|
17985658 |
2007 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
The present study indicates that in the Ouro Preto admixed population the presence of APOE *2 can confer a protective effect, whereas the presence of APOE *4 implies an enhanced risk for dyslipidemia.
|
17224996 |
2007 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Variation in 5' promoter region of the APOE gene contributes to predicting ischemic heart disease (IHD) in the population at large: the Copenhagen City Heart Study.
|
17535270 |
2007 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In recent studies, apolipoprotein E (apo E) genetic polymorphism in association with dyslipidemia have been proposed as the one of the risk factors for the development of diabetic nephropathy.
|
17624465 |
2007 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
In our current study, we have examined the effects of long-term feeding of a 1,3-DAG-rich oil on the dyslipidemia and atherosclerosis in the experimental model of the diabetic apolipoprotein E (apoE)-deficient mouse that develops accelerated atherosclerosis.
|
16996521 |
2007 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The contribution to dyslipidemia of 20 selected single nucleotide polymorphisms of 13 genes reported in the literature to be associated with plasma lipid levels (ABCA1, ADRB2, APOA5, APOC3, APOE, CETP, LIPC, LIPG, LPL, MDR1, MTP, SCARB1, and TNF) was assessed by longitudinally modeling more than 4400 plasma lipid determinations in 438 antiretroviral therapy-treated participants during a median period of 4.8 years.
|
17700364 |
2007 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Variants of apolipoproteins (apo) A5 and C3, interacting with APOE genotypes, have been associated with the severity of antiretroviral therapy-induced dyslipidemia and with occurrence of lipodystrophy, and for APOC3, with objective criteria of fat redistribution.
|
17617020 |
2007 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
LHGDN |
The present study indicates that in the Ouro Preto admixed population the presence of APOE *2 can confer a protective effect, whereas the presence of APOE *4 implies an enhanced risk for dyslipidemia.
|
17224996 |
2007 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A similar phenotype of combined dyslipidemia was induced in apoE(-/-) or apoE(-/-) x LDLr(-/-) mice after infection with a low dose (4 x 10(8) pfu) of an adenovirus expressing the apoE4[R142V/R145V] mutant previously shown to be defective in receptor binding.
|
16339113 |
2006 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The objective of this study was to evaluate 1) whether non single nucleotide polymorphisms-coding (non-cSNP) in the apolipoprotein E gene (APOE) identified by resequencing studies contribute to statistically explaining dyslipidemia if variations in the two cSNPs in exon 4 that define the 2, 3, and 4 alleles are ignored, and 2) whether the contribution of these additional SNPs persists when variations in the cSNPs are considered.
|
16317171 |
2006 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Polymorphism of the apolipoprotein E (APOE) gene has been associated with dyslipidemia and cardiovascular disease.
|
16815257 |
2006 |